Advertisement
Advertisement
U.S. Markets close in 5 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.5116+0.2016 (+15.39%)
As of 10:27AM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • R
    RealGoBig
    Going to the moon pre.market
  • m
    marc
    Calls are going to print money today
    Bullish
  • m
    marc
    Price target raised to $8
    Bullish
  • V
    Vincent
    NEWS for diabetic patients with EDEMA incredible results. NEW GAME
    Bullish
  • D
    Dirk
    Money will be needed for round 3 watch the game boys !
  • S
    STEVEN
    SHARE PRICE WAS $3.48 ONE YEAR AGO TODAY AND THERE ISN'T ANY REASON THAT WE WON'T SEE THAT NUMBER AGAIN REAL SOON. Anirvan Ghosh, Ph.D., chief executive officer of UNITY stated "The sustained and significant improvement in visual acuity after a single injection of UBX1325 is very impressive, and upon approval, could provide an attractive treatment option for patients who currently can only hope to maintain their vision at the cost of frequent injections with current standard of care. We look forward to sharing our 24-week data in BEHOLD as we continue to investigate UBX1325, along with 16-week data in ENVISION, our study in wet age-related macular degeneration.”
    Bullish
  • S
    STEVEN
    The analysts offering 12-month price forecasts for UNITY Biotechnology Inc have a median target of 7.50, with a high estimate of 12.00. The median estimate represents a +380.77% increase from the last price of 1.56. https://money.cnn.com/quote/forecast/forecast.html?symb=UBX
  • D
    DennisF
    Record volume of over 89 mil with float of only 57 M and 69 M outstanding ... chances are good this stock is going higher next week as with this volume everyone took a profit that was going to and traders are doing a lot of flipping. the technical chart breakout over both 50 and 200 MA and other indicators will attract even more traders and the news will bring more buy and hold long term investors which should at least test today's high on Monday and gap up at open.
  • C
    C
    Wake up.
    “It’s going to be a good day Tator.”
    Bullish
  • a
    a b
    i finally do and down it goes...why me??
  • J
    Joe
    $2 today....
  • D
    DennisF
    should gap up strong at open as market makers will try to get as many shares trading as possible both up and down like today and market is on a major rally which is a big plus as the funds that are already in UBX might step in now and buy big blocks
  • K
    Kevin
    UBX goes wild....
  • D
    Dennis
    Found these comments by MDs from yesterdays Phase 2 results / conference call and it seems this is potentially real deal as patients vision improved with just one dose and majority of trial patients are remaining in trials which confirms to me the safety profile with no major side effects which reduces risk of the stock tanking from someone possibly dying or having severe complications which happens sometimes .
    Arshad M. Khanani, MD, MA, FASRS, director of clinical research at Sierra Eye Associates, Reno, Nevada, pointed out that a 6.1-letter gain from baseline in DME patients who had been actively receiving anti-VEGF treatment and had vision loss with persistent fluid is a clinically meaningful outcome.

    “The results are particularly noteworthy considering that there is a progressive improvement in vision through 18 weeks after a single injection of UBX1325,” Khanani said. “A treatment based on a new mechanism of action that shows a meaningful and sustained improvement in BCVA and stability of CST while also reducing the frequency of injections would be of huge value for patients with DME.”

    In outlining the data during the conference call, Robert Bhisitkul, MD, PhD, professor of ophthalmology at University of California San Francisco, noted that the study is a multi-center, randomly assigned, double-masked, sham-controlled study designed to evaluate the safety, tolerability, efficacy and durability of a single 10 mcg dose of UBX1325 in patients with DME evaluated though 24 weeks.

    “In the study, we enrolled 65 patients being actively treated with anti-VEGF immediately prior to the start of the study,” he explained.

    Those patients had a visual acuity deficit (73 ETDRS letters, approximately 20/40, or worse) and residual retinal fluid (CST ≥ 300 μm). Patients have the option of rolling over to a 48-week long term extension and a majority of patients who have completed their 24-week visit have opted to remain in the study.

    Jamie Dananberg, MD, chief medical officer of Unity, pointed out that on the wave of the positive proof-of-concept data, the company believes UBX1325 could represent a much-needed alternative to all other currently available treatments for DME, including the standard of care anti-VEGF therapy.

    “The 12- and 18-week results indicate that a single injection of UBX1325 resulted in significantly greater letter gains and stabilization of retinal structure than the sham treatment, but also likely altered the disease trajectory of these patients who had been on anti-VEGF treatment,” he concluded. “We are greatly encouraged by these findings and look forward to our upcoming 24-week BEHOLD (DME) and 16-week ENVISION (wet AMD) study readouts in the months ahead.”

    Bhisitkul noted that while the two studies share some similarities, they are very different.

    “AMD is a more aggressive and rapidly progressing disease,” he said. “We have seen some extension and support of the Phase 1 data in the Phase 2 data. Hopefully, we will see the same thing in Behold.”
  • I
    IQST EVOSS Electric Vehicles
    UNITY BIOTECH.. SOARING 51 % in a Week and 101 % in a Month as per MarketWatch. Does This Stock Have the Formula to Create LONG-TERM GAIN$..??
    Bullish
  • W
    Warren
    Time to get the reverse split out of the way.
  • S
    Stanislav
    Check out low floater - health care services AMS ($2,4) instead: excellent earning report Q2, profitable, strong balance sheet!
  • D
    DennisF
    If you do google search using UBX technical analysis and click the tradeview technical analysis link it has BUY BUY STRONG BUY for some reason when i tried to post the link my post was not posted.
  • J
    Jeff Manzanita
    I sold 90% of my shares after the knee collapse, and then the SP went down another $3 or $4. I think the science is good, so I held onto some, and am happy I did. Considering adding back more shares.
  • S
    Soren
    No talk of delisting from nasdaq now.
Advertisement
Advertisement